Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on September 22, 2016. The report addresses the closing of an underwritten secondary public offering of Class A common stock.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the completion of a secondary stock offering.
Material Changes
- Secondary Offering Closure: The sale of shares pursuant to the Overallotment Option closed on September 22, 2016.
- Shares Sold: Underwriters exercised their option in full to purchase 1,125,000 additional shares of Class A common stock from Investor Stockholders.
- Total Offering Size: The initial offering consisted of 7,500,000 shares, with the overallotment adding 1,125,000 shares.
- Sellers: Shares were sold by Investor Stockholders (affiliates of TPG Global, The Advisory Board Company, UPMC, Ptolemy Capital) and certain management selling stockholders. The Company did not receive proceeds from this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed in this report beyond the standard disclosure of the transaction completion.
Investor Verification Checklist
- Verify the total number of shares sold in the secondary offering (8,625,000 total).
- Confirm that the Company received no proceeds from this specific transaction.
- Review the September 14, 2016 Form 8-K for the initial terms of the underwriting agreement.
- Check the price per share and total proceeds to selling stockholders in the related prospectus supplement.